title: Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial.
abstract: Dexniguldipine-HCl is a new dihydropyridine compound that exerts selective antiproliferative activity in a variety of tumor models and, in addition, has a high potency in overcoming multidrug resistance. The purpose of this trial was to determine the toxicity and pharmacokinetics of dexniguldipine and to establish a recommended dose for phase II trials. A total of 37 patients with cancer were treated with oral dexniguldipine in increasing doses for up to 7 days. The main parameters evaluated were subjective tolerance and laboratory and cardiovascular parameters (blood pressure and ECG). Blood samples were drawn for analysis of the drug's pharmacokinetics. Dizziness and nausea were the major adverse events observed in seven patients, but episodes were generally mild and not clearly dose-related. Vomiting occurred in one patient. Hypotensive effects and orthostatic dysregulation were observed in some patients but were not considered to be dose-limiting. Therefore, no dose-limiting toxicity was found and the maximally tolerable dose could not be determined. Pharmacokinetic data showed wide interindividual variation and a dose-dependent increase in steady-state serum concentrations at doses of up to 1,000 mg daily, with no clear further increase being observed at higher doses. Consistently high concentrations were achieved with the 2,500-mg dose. Despite the lack of dose-limiting toxicity, higher doses of dexniguldipine do not appear to be useful for clinical evaluation because of the pharmacokinetic properties of the compound: therefore, 2,500 mg/day is recommended as the daily dose for phase II trials.
authors.affiliation: Medizinische Universitäts- und Poliklinik, Abteilung für Pneumologie, Homburg/Saar, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Ukena
authors.forename: C
authors.initials: C
authors.lastname: Boewer
authors.forename: B
authors.initials: B
authors.lastname: Oldenkott
authors.forename: F
authors.initials: F
authors.lastname: Rathgeb
authors.forename: W
authors.initials: W
authors.lastname: Wurst
authors.forename: K
authors.initials: K
authors.lastname: Zech
authors.forename: G W
authors.initials: GW
authors.lastname: Sybrecht
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000633:toxicity*; D017322:Clinical Trials, Phase II as Topic; D004095:Dihydropyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D006261:Headache / Q000139:chemically induced; D006801:Humans; D008657:Metabolic Clearance Rate; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D004095:Dihydropyridines; C054074:niguldipine